Holen Sie sich die Stockscreener-App
2.85
0.00%
0.00
Handel nachbörslich:
2.86
0.010
+0.35%
Schlusskurs vom Vortag:
$2.85
Offen:
$3.16
24-Stunden-Volumen:
8,059
Relative Volume:
0.28
Marktkapitalisierung:
$3.86M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-560.20K
KGV:
-1.9655
EPS:
-1.45
Netto-Cashflow:
$-6.90M
1W Leistung:
-10.38%
1M Leistung:
-1.73%
6M Leistung:
-44.01%
1J Leistung:
-62.25%
1-Tages-Spanne:
$2.85
$3.1901
1-Wochen-Bereich:
$2.84
$3.1901
52-Wochen-Spanne:
$2.72
$8.775
Synaptogenix Inc Stock (SNPX) Company Profile
Firmenname
Synaptogenix Inc
Sektor
Branche
Telefon
(973) 242-0005
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Synaptogenix Inc Aktie (SNPX) Neueste Nachrichten
Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK
Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com
Synaptogenix announces new preferred stock series - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com India
Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World
Synaptogenix extends preferred shares maturity date - Investing.com
Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace
Anitra (AMEX:AZTR) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix - The Pharma Letter
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
New collab to probe potential of fatty acid analogs in Alzheimer's - The Pharma Letter
Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online
Synaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix begins pre-clinical trials for SCI treatment - Investing.com
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury - Lelezard
Virios Therapeutics (NASDAQ:VIRI) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix (NASDAQ:SNPX) Upgraded by Maxim Group to “Buy” - Defense World
Synaptogenix (NASDAQ:SNPX) Trading Down 0.5% - Defense World
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
Synaptogenix Acquires 25% Stake In Cannasoul - Quantisnow
FDA grants IND authorisation for Synaptogenix's multiple sclerosis trial - Yahoo Finance
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix gets FDA nod for multiple sclerosis drug trial By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Dana Incorporated names Lisa Amend as new HR Chief By Investing.com - Investing.com South Africa
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis - StockTitan
Synaptogenix CEO Dr. Tuchman's Tenure Extended Through 2024TipRanks.com - TipRanks
Alzamend Neuro (NASDAQ:ALZN) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix (NASDAQ:SNPX) Stock Price Up 1% - Defense World
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for ... - Investing.com India
Synaptogenix regains Nasdaq listing compliance By Investing.com - Investing.com
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report
What's Going On With Synaptogenix (SNPX) Stock?Synaptogenix (NASDAQ:SNPX) - Benzinga
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com UK
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
Onconetix (NASDAQ:ONCO) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million. - Marketscreener.com
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Finanzdaten der Synaptogenix Inc-Aktie (SNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):